A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
The combination of avelumab plus the FLOT4 regimen showed relatively modest efficacy in resectable G/GEJ adenocarcinoma. Better results were observed in PD-L1 combined positive score ≥10% tumors. Exploratory biomarker analyses provide insights that may help to identify candidates most likely to benefit from chemoimmunotherapy as a neoadjuvant treatment.
Authors
- Eva Martínez de Castro (ORCID: https://orcid.org/0000-0002-5772-0741)
- Marc Díez (ORCID: https://orcid.org/0000-0002-9473-0391)
- Susana Muñoz
- Alena Gros (ORCID: https://orcid.org/0000-0002-1207-1880)
- Josep M. Tabernero (ORCID: https://orcid.org/0000-0002-2495-8139)
- María Alsina (ORCID: https://orcid.org/0000-0003-4835-7159)
- Mariano Ponz‐Sarvisé (ORCID: https://orcid.org/0000-0002-3240-729X)
- Guillermo Villacampa (ORCID: https://orcid.org/0000-0003-4868-6585)
- Ignacio Melero (ORCID: https://orcid.org/0000-0002-1360-348X)
- Enrique Sanz‐García (ORCID: https://orcid.org/0000-0002-3119-3832)
- Carlos E. de Andrea (ORCID: https://orcid.org/0000-0002-7628-8050)
- Eduardo García‐Galea (ORCID: https://orcid.org/0000-0003-4699-0786)
- Paula Jiménez‐Fonseca (ORCID: https://orcid.org/0000-0003-4592-3813)
- Virginia Arrazubi (ORCID: https://orcid.org/0000-0002-1431-2780)
- Dario López
- María C. Ochoa (ORCID: https://orcid.org/0000-0001-9920-2144)
- Álvaro López‐Janeiro (ORCID: https://orcid.org/0000-0002-5744-3115)
- Cristina Bugés (ORCID: https://orcid.org/0000-0003-2013-1510)
- Raluca Alexandru (ORCID: https://orcid.org/0009-0002-1903-5636)
- María Vila-Casadesús (ORCID: https://orcid.org/0000-0001-6597-7953)
- Ana P. Vivancos (ORCID: https://orcid.org/0000-0003-2888-6512)
- Sandra Sánchez‐Gregorio (ORCID: https://orcid.org/0000-0003-1797-3397)
- Federico Longo (ORCID: https://orcid.org/0000-0003-0902-2188)
- Vı́ctor Navarro (ORCID: https://orcid.org/0000-0001-6925-4605)
- Raquel Guardeño (ORCID: https://orcid.org/0000-0002-6462-132X)
- Claudia Herrero
- Mariona Calvo (ORCID: https://orcid.org/0000-0001-6242-0500)
- Ibone Labiano (ORCID: https://orcid.org/0000-0001-8901-9653)
Institutions
- Universitat de Vic - Universitat Central de Catalunya (ES)
- University Health Network (CA)
- Nuffield Orthopaedic Centre (GB)
- Princess Margaret Cancer Centre (CA)
- University of Oxford (GB)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Complejo Hospitalario de Navarra (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Institut Català d'Oncologia (ES)
- Instituto de Investigación Marqués de Valdecilla (ES)
- Navarrabiomed (ES)
- Instituto Ramón y Cajal de Investigación Sanitaria (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitario Central de Asturias (ES)
- Clinica Universidad de Navarra (ES)
- Hospital Universitario HM Sanchinarro (ES)
- Duran i Reynals Hospital (ES)
- Hospital Universitari de Girona Doctor Josep Trueta (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Vall d'Hebron Institute of Oncology (ES)
- Universidad de Navarra (ES)
- Chartered Institute of Management Accountants (GB)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0369
- Citations
- 4
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Fundación Cellex
- Regeneron Pharmaceuticals
- Merck KGaA
- Jazz Pharmaceuticals
- Centres de Recerca de Catalunya
- BeiGene
- Incyte
- Generalitat de Catalunya
- Daiichi-Sankyo
- Astellas Pharma
- Servier
- Agencia Estatal de Investigación
- Daiichi Sankyo Europe